These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

552 related articles for article (PubMed ID: 30319054)

  • 1. Assessment of the clinicopathological relevance of mesothelin level in plasma, peritoneal fluid, and tumor tissue of epithelial ovarian cancer patients.
    Okła K; Surówka J; Frąszczak K; Czerwonka A; Kaławaj K; Wawruszak A; Kotarski J; Wertel I
    Tumour Biol; 2018 Oct; 40(10):1010428318804937. PubMed ID: 30319054
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Co-Expression of Mesothelin and CA125 Is Associated with the Poor Prognosis of Endometrial Serous Carcinoma and Mixed Carcinomas Including Serous Carcinoma.
    Kakimoto S; Miyamoto M; Einama T; Matsuura H; Iwahashi H; Ishibashi H; Sakamoto T; Hada T; Takano M
    Pathol Oncol Res; 2020 Oct; 26(4):2299-2306. PubMed ID: 32468249
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Elevated growth differentiation factor 15 expression predicts poor prognosis in epithelial ovarian cancer patients.
    Zhang Y; Hua W; Niu LC; Li SM; Wang YM; Shang L; Zhang C; Li WN; Wang R; Chen BL; Xin XY; Zhang YQ; Wang J
    Tumour Biol; 2016 Jul; 37(7):9423-31. PubMed ID: 26781874
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HE4 and mesothelin: novel biomarkers of ovarian carcinoma in patients with pelvic masses.
    Abdel-Azeez HA; Labib HA; Sharaf SM; Refai AN
    Asian Pac J Cancer Prev; 2010; 11(1):111-6. PubMed ID: 20593939
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mucinous, endometrioid, and serous ovarian cancers with peritoneal dissemination are potent candidates for P-cadherin targeted therapy: a retrospective cohort study.
    Kayahashi K; Mizumoto Y; Matsuoka A; Obata T; Iwadare J; Nakamura M; Daikoku T; Fujiwara H
    BMC Cancer; 2021 Jan; 21(1):32. PubMed ID: 33413178
    [TBL] [Abstract][Full Text] [Related]  

  • 6. EphA8 is a prognostic marker for epithelial ovarian cancer.
    Liu X; Xu Y; Jin Q; Wang W; Zhang S; Wang X; Zhang Y; Xu X; Huang J
    Oncotarget; 2016 Apr; 7(15):20801-9. PubMed ID: 26989075
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CA-125 level as a prognostic indicator in type I and type II epithelial ovarian cancer.
    Chen X; Zhang J; Cheng W; Chang DY; Huang J; Wang X; Jia L; Rosen DG; Zhang W; Yang D; Gershenson DM; Sood AK; Bast RC; Liu J
    Int J Gynecol Cancer; 2013 Jun; 23(5):815-22. PubMed ID: 23669443
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Should All Cases of High-Grade Serous Ovarian, Tubal, and Primary Peritoneal Carcinomas Be Reclassified as Tubo-Ovarian Serous Carcinoma?
    Moss EL; Evans T; Pearmain P; Askew S; Singh K; Chan KK; Ganesan R; Hirschowitz L
    Int J Gynecol Cancer; 2015 Sep; 25(7):1201-7. PubMed ID: 26035124
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pattern of tissue expression of CA-125 and HE4 in primary epithelial ovarian tumours and correlation with serum CA-125 levels.
    Devan SM; Pailoor J; Sthaneshwar P; Narayanan V
    Asian Pac J Cancer Prev; 2013; 14(8):4545-8. PubMed ID: 24083699
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic impact of Dynamin related protein 1 (Drp1) in epithelial ovarian cancer.
    Tsuyoshi H; Orisaka M; Fujita Y; Asare-Werehene M; Tsang BK; Yoshida Y
    BMC Cancer; 2020 May; 20(1):467. PubMed ID: 32448194
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Outcome in serous ovarian cancer is not associated with LATS expression.
    Montavon C; Stricker GR; Schoetzau A; Heinzelmann-Schwarz V; Jacob F; Fedier A
    J Cancer Res Clin Oncol; 2019 Nov; 145(11):2737-2749. PubMed ID: 31586262
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neutrophil to lymphocyte and platelet to lymphocyte ratios increase in ovarian tumors in the presence of frank stromal invasion.
    Polat M; Senol T; Ozkaya E; Ogurlu Pakay G; Cikman MS; Konukcu B; Ozten MA; Karateke A
    Clin Transl Oncol; 2016 May; 18(5):457-63. PubMed ID: 26289552
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Programmed Death Ligand 1 (PD-L1) Expression in Epithelial Ovarian Cancer: A Comparison of Type I and Type II Tumors.
    Nhokaew W; Kleebkaow P; Chaisuriya N; Kietpeerakool C
    Asian Pac J Cancer Prev; 2019 Apr; 20(4):1161-1169. PubMed ID: 31030490
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression and clinical significance of Ki-67, E-cadherin, and mesothelin in serous borderline ovarian tumor.
    Yu N; Wang N; Liu YF; Li YY; Zhang TG
    Eur J Gynaecol Oncol; 2017; 38(1):85-90. PubMed ID: 29767871
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Correlation of preoperative ROMA scores with clinical stage in epithelial ovarian cancer patients.
    Li QL; Wang CJ; Qi P; Zhang YX
    Clin Transl Oncol; 2017 Oct; 19(10):1260-1267. PubMed ID: 28444641
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oviductal glycoprotein (OVGP1, MUC9): a differentiation-based mucin present in serum of women with ovarian cancer.
    Maines-Bandiera S; Woo MM; Borugian M; Molday LL; Hii T; Gilks B; Leung PC; Molday RS; Auersperg N
    Int J Gynecol Cancer; 2010 Jan; 20(1):16-22. PubMed ID: 20130498
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biparametric Magnetic Resonance Imaging as an Adjunct to CA125 and HE4 to Improve Characterization of Large Ovarian Masses.
    Manganaro L; Anastasi E; Porpora MG; Vinci V; Saldari M; Bernardo S; Ballesio L; Sollazzo P; Pecorella I; Recchia N; Stracci F; Panici PB; Angeloni A; Catalano C; Scialpi M
    Anticancer Res; 2015 Nov; 35(11):6341-51. PubMed ID: 26504074
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CD105/Ki67 coexpression correlates with tumor progression and poor prognosis in epithelial ovarian cancer.
    Liu P; Sun YL; Du J; Hou XS; Meng H
    Int J Gynecol Cancer; 2012 May; 22(4):586-92. PubMed ID: 22266931
    [TBL] [Abstract][Full Text] [Related]  

  • 19. FGF18 as a potential biomarker in serous and mucinous ovarian tumors.
    El-Gendi S; Abdelzaher E; Mostafa MF; Sheasha GA
    Tumour Biol; 2016 Mar; 37(3):3173-83. PubMed ID: 26427667
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Calpain system protein expression and activity in ovarian cancer.
    Zhang S; Deen S; Storr SJ; Chondrou PS; Nicholls H; Yao A; Rungsakaolert P; Martin SG
    J Cancer Res Clin Oncol; 2019 Feb; 145(2):345-361. PubMed ID: 30448882
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.